Brokerages Set Savara Inc (NASDAQ:SVRA) PT at $9.86

Savara Inc (NASDAQ:SVRA) has been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.86.

A number of brokerages recently commented on SVRA. Wells Fargo & Company assumed coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price for the company. HC Wainwright dropped their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Finally, Evercore ISI reiterated an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th.

Insider Buying and Selling at Savara

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of Savara stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.13% of the stock is owned by company insiders.

Institutional Trading of Savara

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. increased its holdings in shares of Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares during the period. Nantahala Capital Management LLC increased its stake in Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares during the period. Farallon Capital Management LLC raised its position in Savara by 90.5% during the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock worth $18,377,000 after buying an additional 2,165,701 shares during the last quarter. First Light Asset Management LLC acquired a new stake in shares of Savara in the 2nd quarter worth $8,069,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Savara by 22.9% in the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Stock Performance

NASDAQ:SVRA opened at $3.14 on Wednesday. The firm has a market capitalization of $538.88 million, a price-to-earnings ratio of -7.30 and a beta of 0.68. Savara has a 1-year low of $2.82 and a 1-year high of $5.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company’s 50-day moving average is $3.39 and its two-hundred day moving average is $3.92.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). Analysts forecast that Savara will post -0.45 EPS for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.